News articles about Insmed (NASDAQ:INSM) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.6662503227546 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Insmed (NASDAQ:INSM) traded up $0.40 on Friday, hitting $30.54. 192,238 shares of the stock traded hands, compared to its average volume of 590,778. Insmed has a 52 week low of $11.49 and a 52 week high of $32.94. The company has a debt-to-equity ratio of 0.13, a quick ratio of 15.21 and a current ratio of 15.21.

Several analysts have issued reports on the stock. BidaskClub lowered shares of Insmed from a “sell” rating to a “strong sell” rating in a research report on Monday, August 14th. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Wednesday, August 2nd. Evercore ISI assumed coverage on shares of Insmed in a research report on Wednesday, August 16th. They set an “outperform” rating and a $28.00 price target on the stock. Cowen Inc reaffirmed a “buy” rating and set a $54.00 price target on shares of Insmed in a research report on Friday, November 3rd. Finally, ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $34.50.

In other news, Director Donald J. Hayden, Jr. sold 15,000 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total value of $487,500.00. Following the transaction, the director now directly owns 71,131 shares of the company’s stock, valued at $2,311,757.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Melvin Md Sharoky sold 50,000 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $27.37, for a total transaction of $1,368,500.00. The disclosure for this sale can be found here. Insiders sold 110,000 shares of company stock worth $3,191,150 over the last three months. Insiders own 4.03% of the company’s stock.

WARNING: “Insmed (INSM) Getting Somewhat Favorable Press Coverage, Analysis Finds” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/insmed-insm-getting-somewhat-favorable-press-coverage-analysis-finds/1727958.html.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.